Generic Name and Formulations:
Lansoprazole 15mg, 30mg; e-c del-rel granules in caps.
Takeda Pharmaceutical Company
Indications for PREVACID:
Triple therapy (w. amoxicillin + clarithromycin) or dual therapy (w. amoxicillin; use only if allergic, intolerant, or resistant to clarithromycin) for H. pylori eradication in duodenal ulcer disease. Short-term treatment of active duodenal ulcer, active benign gastric ulcer, erosive esophagitis (EE), symptomatic GERD, and NSAID-associated gastric ulcers when NSAID use is continued. To reduce risk of NSAID-associated gastric ulcer in patients with history of gastric ulcer who need an NSAID. Maintenance of healing of duodenal ulcer, EE. Long-term treatment of pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome).
Take before eating. Do not crush or chew granules. Caps: swallow whole, or sprinkle granules and mix contents with food or juice (see full labeling) and take immediately. May open caps and mix granules in 40mL apple juice and give via NG tube; flush tube with more juice. SoluTabs: dissolve on tongue; swallow with or without water. May give via oral syringe or NG tube (see full labeling). ≥18yrs: Triple therapy: lansoprazole 30mg + amoxicillin 1g + clarithromycin 500mg, all every 12hrs for 10 or 14 days. Dual therapy: lansoprazole 30mg + amoxicillin 1g, both every 8hrs for 14 days. Duodenal ulcer: 15mg once daily for 4 weeks. Gastric ulcer treatment: 30mg once daily for up to 8 weeks. EE treatment: 30mg once daily for up to 8 weeks; may repeat for 8 more weeks. If relapse occurs, may repeat 8-week course. GERD: 15mg once daily for up to 8 weeks. Maintenance of healing of duodenal ulcer or EE: 15mg once daily. Healing of NSAID-associated gastric ulcer: 30mg once daily for 8 weeks; NSAID ulcer risk reduction: 15mg once daily for up to 12 weeks. Hypersecretory conditions: Initially 60mg once daily, adjust as needed; give daily doses >120mg in divided doses. Severe hepatic impairment: 15mg once daily.
Take before eating. Do not crush or chew granules. Caps: swallow whole, or sprinkle granules and mix contents with food or juice (see full labeling) and take immediately. May open caps and mix granules in 40mL apple juice and give via NG tube; flush tube with more juice. SoluTabs: dissolve on tongue; swallow with or without water. May give via oral syringe or NG tube (see full labeling). GERD or EE: ≤1yr: not recommended. 1–11yrs: ≤30kg: 15mg once daily; >30kg: 30mg once daily. For both: give for up to 12 weeks; doses up to 30mg twice daily have been used. Severe hepatic impairment: 15mg once daily.
Concomitant rilpivirine-containing products.
Symptomatic response does not preclude gastric malignancy. Discontinue if acute interstitial nephritis, cutaneous/systemic lupus erythematosus occurs. Long-term therapy (eg, >3yrs) may lead to malabsorption/deficiency of Vit. B12. Monitor magnesium levels during prolonged therapy. Increased risk of fundic gland polyps with long-term use (esp. >1yr) or osteoporosis-related fractures (hip, wrist or spine) with long-term (>1yr) and multiple daily dose PPI therapy. Use lowest dose for shortest duration appropriate to condition. SoluTabs: phenylketonuria. Severe hepatic impairment: reduce dose. Pregnancy. Nursing mothers.
Proton pump inhibitor.
Concomitant St. John's wort, rifampin, atazanavir, nelfinavir: not recommended. May potentiate digoxin, tacrolimus, methotrexate, saquinavir; monitor. Potentiated by voriconazole. May alter absorption of pH-dependent drugs (eg, ketoconazole/itraconazole, iron salts, erlotinib, mycophenolate mofetil, dasatinib, nilotinib). Concomitant digoxin, diuretics may predispose patients to hypomagnesemia. Monitor theophylline, warfarin. Give at least 30 mins before sucralfate. May give antacids concomitantly. May interfere with neuroendocrine tumor diagnostic tests; discontinue lansoprazole at least 14 days prior to CgA level assessment. Interrupt therapy at least 28 days before secretin stimulation test. May cause false (+) urine screening tests for THC.
Diarrhea, abdominal pain, nausea, constipation, headache, bone fracture; possible C. difficile-associated diarrhea (esp. if hospitalized); rare: hypomagnesemia.
See Amoxil entry for more information on amoxicillin. See Biaxin entry for more information on clarithromycin.
Hepatic. 97% protein bound.
Biliary, renal, fecal.
Caps 15mg—30, 100, 1000; 30mg—100, 1000; SoluTabs—100
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Qualitative Analysis of Myeloma Patients' Experience Following Hematopoietic Stem Cell Transplant
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Involved-Field Radiotherapy Plus Chemotherapy Prolonged PFS in Follicular Lymphoma
- Patient Fears of Placebo Use in Clinical Trials
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|